BFM
EBS icon

Boothbay Fund Management’s Emergent Biosolutions EBS Stock Holding History

Boothbay Fund Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,386
Closed -$250K – 640
2017
Q2 		$250K Buy
+7,386
New +$228K 0.05% 476

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Boothbay Fund Management's EBS Position: Q3 2017 in Review

Boothbay Fund Management sold out of Emergent Biosolutions (EBS) in Q3 2017, closing a stake of 7,386 shares — an estimated $250K sold.

Boothbay Fund Management first reported a position in EBS in Q2 2017 and held it in 1 quarter. The position peaked at $250K in Q2 2017. 198 funds tracked by Wall St. Rank hold EBS as of Q3 2017.

  • Boothbay Fund Management reported no remaining Emergent Biosolutions position as of Q3 2017 after selling out during the quarter.
  • Boothbay Fund Management sold 7,386 Emergent Biosolutions shares in Q3 2017, an estimated $250K.
  • Boothbay Fund Management first reported a position in Emergent Biosolutions in Q2 2017 and held it in 1 quarter.
  • Boothbay Fund Management's Emergent Biosolutions position peaked at $250K in Q2 2017.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2017.

Based on Boothbay Fund Management's 13F filing for Q3 2017, filed 14 Nov 2017.